Number of the records: 1
lenalidomid
SYS d000077269 LBL 00000nz--a2200181n--4500 005 20250606222642.0 008 190101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D02.241.223.805.810.400 065 $a D03.383.621.808.519 065 $a D03.633.100.513.750.563 066 $a 01 $c 03 150 $a lenalidomid $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a 2,6-piperidíndion, 3-(4-amino-1,3-dihydro-1-oxo-2H- izoindol-2-yl)- $2 slo 450 $w v $a 3-(4-amino-1-oxoizoindolín-2-yl)piperidíne-2,6-dion $2 slo 450 $w v $a Revimid $2 slo 450 $w v $a Revlimid $2 slo 550 $7 sllk_us_auth*d007155 $Y Immunologic Factors $w P $a faktory imunologické 550 $7 sllk_us_auth*d020533 $Y Angiogenesis Inhibitors $w P $a inhibítory angiogenézy 665 $a 2019 (2002) $2 eng 680 9-
$i A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. $2 eng 750 -2
$a Lenalidomide $2 eng 980 $x M
Number of the records: 1